A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia
Phase of Trial: Phase II
Latest Information Update: 16 Sep 2019
Price : $35 *
At a glance
- Drugs Parsaclisib (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Incyte Corporation
- 23 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Sep 2020.
- 23 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Sep 2020.
- 25 Jul 2018 Status changed from not yet recruiting to recruiting.